Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 6, 2016

G1 Therapeutics and Genentech to evaluate Phase II lung cancer trial of tecentriq and trilaciclib

US-based clinical-stage oncology company G1 Therapeutics has collaborated with Genentech to conduct a Phase II clinical trial of tecentriq and trilaciclib to treat patients with small-cell lung cancer (SCLC) receiving chemotherapy.

US-based clinical-stage oncology company G1 Therapeutics has collaborated with Genentech to conduct a Phase II clinical trial of tecentriq and trilaciclib to treat patients with small-cell lung cancer (SCLC) receiving chemotherapy.

G1’s trilaciclib (G1T28) is a short-acting intravenous CDK4/6 inhibitor that is being developed to sustain hematopoietic stem cells and enhance immune system function during chemotherapy.

Genetech’s tecentriq is an anti-PD-L1 monoclonal antibody that binds to PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, thereby inhibiting its interactions with both PD-1 and B7.1 receptors.

G1 Therapeutics CEO Mark Velleca said: “We are excited that this combination regimen of trilaciclib plus Tecentriq may benefit patients with small-cell lung cancer, a disease with tremendous unmet medical need.

"We are excited that this combination regimen of trilaciclib plus Tecentriq may benefit patients with small-cell lung cancer, a disease with tremendous unmet medical need."

“Trilaciclib has demonstrated its ability to preserve the immune system from damage by chemotherapy and to enhance T-cell activation, which may augment anti-tumour immunity and be a powerful complement to Tecentriq.”

Expected to commence next year, the drug combination will be applied as a first-line treatment for small-cell lung cancer patients.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Trilaciclib has demonstrated its anti-tumour activity, including a complete response and multiple partial responses, while applied in combination with chemotherapy to patients with SCLC during two ongoing Phase Ib/IIa trials.

The treatment was favourably tolerated, with no occurrence of febrile neutropenia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU